This economic evaluation examines which drugs and therapeutic classes contribute to the most savings in the Generating Cost Reductions for US Medicaid model inclusive of statutory and supplemental rebates.
No takes yet. Share an insight, caveat, or question.
Ballreich et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: